JPS6357438B2 - - Google Patents
Info
- Publication number
- JPS6357438B2 JPS6357438B2 JP16662584A JP16662584A JPS6357438B2 JP S6357438 B2 JPS6357438 B2 JP S6357438B2 JP 16662584 A JP16662584 A JP 16662584A JP 16662584 A JP16662584 A JP 16662584A JP S6357438 B2 JPS6357438 B2 JP S6357438B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- carried out
- compound
- acetal
- oxidation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 claims description 85
- 150000001875 compounds Chemical class 0.000 claims description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 17
- -1 dibromo compound Chemical class 0.000 claims description 17
- 239000002585 base Substances 0.000 claims description 16
- 238000007254 oxidation reaction Methods 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 230000007935 neutral effect Effects 0.000 claims description 14
- 230000003647 oxidation Effects 0.000 claims description 14
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 11
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 229910052744 lithium Inorganic materials 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000005893 bromination reaction Methods 0.000 claims description 10
- 150000003566 thiocarboxylic acids Chemical class 0.000 claims description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical compound [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 claims description 8
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 8
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 150000001241 acetals Chemical class 0.000 claims description 6
- 239000003929 acidic solution Substances 0.000 claims description 6
- 125000005035 acylthio group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 claims description 6
- 230000031709 bromination Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 claims description 4
- 229940117975 chromium trioxide Drugs 0.000 claims description 4
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 claims description 4
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 4
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- QFZCFQWLHKRQHC-SJFWLOONSA-N 2-[(8s,9s,10r,13r,14s,17r)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]acetaldehyde Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)CC=O)[C@@H]4[C@@H]3CC=C21 QFZCFQWLHKRQHC-SJFWLOONSA-N 0.000 claims description 2
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims 1
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 15
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical class C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 15
- 229960002847 prasterone Drugs 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 229960002256 spironolactone Drugs 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000007795 chemical reaction product Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 150000002168 ethanoic acid esters Chemical class 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- NKRNGKIEDAVMHL-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical compound O[Cr](O)(=O)=O.C1=CC=NC=C1 NKRNGKIEDAVMHL-UHFFFAOYSA-L 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- GBKZPLIJKMRYTE-UHFFFAOYSA-N 2-(2-chloroethyl)-1,3-dioxolane Chemical compound ClCCC1OCCO1 GBKZPLIJKMRYTE-UHFFFAOYSA-N 0.000 description 2
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 229940061641 androsterone Drugs 0.000 description 2
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 2
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N propionic aldehyde Natural products CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000011833 salt mixture Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- ZZPMGSLVNVERCX-UHFFFAOYSA-N 2-(1-chloroethyl)-1,3-dioxolane Chemical compound CC(Cl)C1OCCO1 ZZPMGSLVNVERCX-UHFFFAOYSA-N 0.000 description 1
- UAARVZGODBESIF-UHFFFAOYSA-N 2-chloropropanal Chemical compound CC(Cl)C=O UAARVZGODBESIF-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001845 chromium compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000007269 dehydrobromination reaction Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 125000000686 lactone group Chemical group 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical class [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 235000011160 magnesium carbonates Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- OTIJNTWWDCIUNM-UHFFFAOYSA-N pentanethioic s-acid Chemical compound CCCCC(S)=O OTIJNTWWDCIUNM-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- KOODSCBKXPPKHE-UHFFFAOYSA-N propanethioic s-acid Chemical compound CCC(S)=O KOODSCBKXPPKHE-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000011182 sodium carbonates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- DDFYFBUWEBINLX-UHFFFAOYSA-M tetramethylammonium bromide Chemical compound [Br-].C[N+](C)(C)C DDFYFBUWEBINLX-UHFFFAOYSA-M 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/001—Lactones
- C07J21/003—Lactones at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Description
【発明の詳細な説明】
本発明は、ステロイドカルボン酸ラクトン、殊
に式
(この式でR1はα―アシルチオ基であつてR2
は水素原子である)
で表わされる3―オキソ―17α―プレグナン―4
―エン―21,17―カルボン酸ラクトンの製法に関
するものである。上記アシルチオ基は殊に低級ア
シルチオ基、主としてアセルチルチオ基である。DETAILED DESCRIPTION OF THE INVENTION The present invention provides steroidal carboxylic acid lactones, particularly those of the formula (In this formula, R 1 is an α-acylthio group, and R 2
is a hydrogen atom) 3-oxo-17α-pregnane-4 represented by
-Ene-21,17-Carboxylic acid lactone production method. The above-mentioned acylthio groups are especially lower acylthio groups, mainly acertylthio groups.
これら化合物は公知のアルドステロン―拮抗
剤、例えばスピロノラクトン〔式()における
R1がアセチルチオ基である化合物であつて、ア
ルダクトンAの商品名で販売されている〕であ
る。 These compounds are known aldosterone antagonists, such as spironolactone [formula ()]
It is a compound in which R 1 is an acetylthio group, and is sold under the trade name Aldactone A].
式()の化合物の製法としては、文献および
特許明細書に多くの方法が提案されている。例え
ば、J.Am.Chem.Soc.,79,4808および米国特許
第2705712号明細書には、式()におけるR1と
R2とが両方で6,7―C・C結合を表わす化合
物の製法が記載されている。この製法を工程的に
次のように行うことができる(方法A)。 Many methods have been proposed in literature and patent specifications for producing the compound of formula (). For example, in J.Am.Chem.Soc., 79, 4808 and U.S. Patent No. 2705712, R 1 in formula () and
A method for preparing a compound in which R 2 and R 2 both represent a 6,7-C·C bond is described. This manufacturing method can be carried out as follows (method A).
Rがアシルチオ基殊にアセチルチオ基である相
当する化合物は、上記式()の化合物を例えば
ドイツ特許第1121610号明細書に記載の方法によ
つてチオカルボン酸殊にチオ酢酸と反応させるこ
とにより作られる。 Corresponding compounds in which R is an acylthio group, especially an acetylthio group, are prepared by reacting a compound of the above formula () with a thiocarboxylic acid, especially a thioacetic acid, for example by the method described in German Patent No. 1 121 610. .
式()の4,6―ジエン化合物を作る前記の
方法は収率が不十分であるために現在では時代遅
れと見做すべきである。改良方法は米国特許第
3738983号および第3270008号明細書に記載されて
おり、次の工程で行う(方法B)。 The above-mentioned method for preparing 4,6-diene compounds of formula () should now be considered obsolete due to insufficient yields. The improved method is described in U.S. Patent No.
No. 3738983 and No. 3270008, and is carried out in the following steps (method B).
さらに、ドイツ特許公開第2237143号明細書に
は次の工程によるスピロノラクトンの製法が記載
されている(方法C)。 Further, German Patent Application No. 2237143 describes a method for producing spironolactone according to the following steps (method C).
この方法の変形はドイツ特許公開第2248834号
明細書(方法D)そしてさらに別の変形はドイツ
特許公開第2248835号明細書(方法E)に記載さ
れている。 A variant of this method is described in DE 22 48 834 (Method D) and a further variant in DE 22 48 835 (Method E).
さらに、ドイツ特許公開第2251476号明細書に
は他の変形が記載されている。これによれば、前
記の式()の化合物に相当する3―オキソ―
4,6―ジエン誘導体から出発し、これにチオ酢
酸を付加し、得られた相当する3―オキソ―7α
―アセチルチオ―4―エン誘導体(これは17β―
ヒドロキシ―17α―プロピオンアルデヒドアセタ
ール側鎖をそのまま保持している)を酸性溶液中
で酸化してスピロノラクトンとなすのである。こ
の原料中の17―位置の置換基を保持したまま6,
7―2重結合にチオ酢酸が付加するのは意外であ
ると上記特許明細書に記載されている。その理由
は、酸性媒質中でチオ酢酸は次のように環化をも
たらすものと当然期待されるからである。 Furthermore, other variants are described in DE 22 51 476 A1. According to this, 3-oxo- which corresponds to the compound of the above formula ()
Starting from a 4,6-diene derivative and adding thioacetic acid to it, the corresponding 3-oxo-7α obtained
-acetylthio-4-ene derivative (this is 17β-
Hydroxy-17α-propionaldehyde (with the acetal side chain intact) is oxidized to spironolactone in an acidic solution. 6, while retaining the substituent at the 17-position in this raw material.
The above patent specification states that it is surprising that thioacetic acid is added to the 7-double bond. The reason is that thioacetic acid in an acidic medium is naturally expected to bring about cyclization as follows.
しかし、この方法を実験的に再検討した結果、
原料として使う前記の17β―ヒドロキシ―17α―
プロピオンアルデヒドアセタール側鎖をもつ3―
オキソ―4,6―ジエンは全く認められずそして
上記ドイツ特許公開第2251476号明細書記載の方
法によつても製造できないことが判つた。すなわ
ち、前記ドイツ特許公開第2237143号および第
2248834号明細書(ドイツ特許公開第251476号明
細書4頁に引用されている)に記載の方法によつ
て得た17β―ヒドロキシ―17α―プロピオンアル
デヒドアセタール側鎖をもつ3―オキソ―4―エ
ンをクロラニルで脱水(米国特許第3137690号明
細書に記載の方法によつて行う。これはドイツ特
許公開第2251476号明細書4頁および実験例12頁
にも引用されている)したが、相当する4,6―
ジエンが生成せずに前記工程図によつて生成する
環状誘導体の4,6―ジエンが生成した。この場
合に、アセチルチオ基の代りに溶媒として使つた
アルコールから導かれたエーテル基が存在するこ
とがある。従つて、ドイツ特許公開第2251476号
明細書に記載の方法は実施できない。 However, as a result of reexamining this method experimentally,
The above-mentioned 17β-hydroxy-17α- used as a raw material
3- with propionaldehyde acetal side chain
It was found that no oxo-4,6-diene was observed and that it could not be produced even by the method described in DE 2251476 mentioned above. Namely, the above-mentioned German Patent Publications No. 2237143 and No.
3-oxo-4-ene with 17β-hydroxy-17α-propionaldehyde acetal side chain obtained by the method described in German Patent Publication No. 2248834 (cited on page 4 of German Patent Publication No. 251476) was dehydrated with chloranil (carried out by the method described in US Pat. No. 3,137,690, which is also cited in DE 2,251,476, page 4 and experimental example, page 12), but the corresponding 4,6-
No diene was produced, but 4,6-diene, a cyclic derivative produced according to the above process diagram, was produced. In this case, an ether group derived from the alcohol used as a solvent may be present in place of the acetylthio group. Therefore, the method described in DE 2251476 cannot be carried out.
式()のカルボン酸ラクトンを製造する前記
の方法はいずれも操作技術の観点から不満足であ
る。初めに発表された方法Aでは実施技術上あま
り適さない反応、例えば第2段階における長時間
にわたる2酸化炭素処理および第3段階における
接触水素処理を必要としている。さらに、その収
率は極めて僅かである。 All of the above-mentioned methods for preparing carboxylic acid lactones of formula () are unsatisfactory from the point of view of operating technology. The originally published method A requires reactions that are not well suited for implementation, such as a prolonged carbon dioxide treatment in the second stage and a catalytic hydrogen treatment in the third stage. Furthermore, the yield is extremely low.
方法Bでは後処理操作によつて収率は使用した
デヒドロ―エビ―アンドロステロンに関して約20
重量%である。なお、このデヒドロ―エピ―アン
ドロステロンは工程第1段階に記載の17α―エチ
ニル―アンドロスト―5―エン―3β―,17β―ジ
オールの製造用原料として使われるものである。 In method B, due to work-up operations, the yield is approximately 20% with respect to the dehydro-shrimp androsterone used.
Weight%. Note that this dehydro-epi-androsterone is used as a raw material for producing 17α-ethynyl-androst-5-ene-3β-,17β-diol described in the first step of the process.
方法(C)〜(E)では、当該特許明細書の実験例によ
る収率は使用したデヒドロ―エピ―アンドロステ
ロンに関して10〜23%の範囲にある。 For processes (C) to (E), the yields according to the experimental examples of the patent range from 10 to 23% with respect to the dehydro-epi-androsterone used.
本発明者は、収率が今迄の収率よりも高くそし
て操作技術の観点においても今迄よりも簡単かつ
適切であり、さらに再現性のある式()の化合
物の製法を見出した。 The present inventors have found a method for preparing the compound of formula () which has a higher yield than hitherto and which is simpler and more suitable from the point of view of the operating technique than hitherto and which is more reproducible.
本発明方法は、3β,17―ジヒドロキシ―17α―
プレグナン―5―エン―21―アルデヒドのアセタ
ールを塩基性ないし中性の媒質中で2重結合えの
臭素付加に適する臭素化剤で処理し、こうして得
た5,6―ジブロモ化合物を塩基性ないし中性の
条件の下で6価クロム化合物で酸化し、得られた
生成物から臭化水素を脱離し、そしてこうして得
た生成物を、7α―アシルチオ基に相当するチオ
カルボン酸で予め処理した後、酸性溶液中6価ク
ロム化合物で処理することを含んでなる。 The method of the present invention provides 3β,17-dihydroxy-17α-
The acetal of pregnane-5-ene-21-aldehyde is treated with a brominating agent suitable for the bromination of the double bond in a basic to neutral medium, and the 5,6-dibromo compound thus obtained is treated with a basic to neutral medium. After oxidation with a hexavalent chromium compound under neutral conditions to eliminate hydrogen bromide from the product obtained, and after pretreatment of the product thus obtained with a thiocarboxylic acid corresponding to the 7α-acylthio group. , treatment with a hexavalent chromium compound in an acidic solution.
上記原料の5,6―2重結合に臭素を付加する
には、2重結合に臭素を一般に付加することので
きる臭素化剤を使つて行うことができる。この場
合に、反応を塩基性ないし中性の媒質中で行うよ
うにする。従つてこの付加反応をそれ自体公知の
方法によつて、例えば不活性溶媒例えばエチレン
クロライドやクロロホルムのようなハロゲン化さ
れた炭化水素がジメチルホルムアミドのようなジ
低級アルキル―低級アルカン酸アミドの中で、所
望ならば有機または無機塩基のような緩衝剤の存
在の下で臭素を使うかまたは過剰に使つた有機窒
素塩基例えばピリジンまたはそのC―メチル同族
体例えばピコリンまたは殊にコリジンのような第
3有機芳香族塩基の中で臭素を使つて行うことが
できる。臭素はこれら窒素塩基と共に中間的にパ
ーブロマイドまたはこの塩基のハロゲン化水素酸
塩のパーブロマイド、例えば臭化水素酸塩のパー
ブロマイドを形成する。このようなパーブロマイ
ドも本発明による臭素化反応に有利に使うことが
できる。殊にピリジンハイドロブロマイドパーブ
ロマイドを使う。なお、2重結合の臭素化に要す
る理論量より僅かに過剰な量で臭素を使うのが有
利である。 Addition of bromine to the 5,6-double bond of the above-mentioned raw material can be carried out using a brominating agent that can generally add bromine to a double bond. In this case, the reaction is carried out in a basic to neutral medium. This addition reaction can therefore be carried out in a manner known per se, for example by reacting a halogenated hydrocarbon such as an inert solvent such as ethylene chloride or chloroform in a di-lower alkyl-lower alkanoic acid amide such as dimethylformamide. , if desired in the presence of a buffer such as an organic or inorganic base, using bromine or an organic nitrogen base such as pyridine or its C-methyl analogue such as picoline or especially collidine. This can be done using bromine among organic aromatic bases. Bromine forms intermediately with these nitrogenous bases perbromide or perbromide of the hydrohalide salt of this base, for example perbromide of the hydrobromide salt. Such perbromides can also be advantageously used in the bromination reaction according to the invention. In particular, pyridine hydrobromide perbromide is used. In addition, it is advantageous to use bromine in an amount slightly in excess of the theoretical amount required for bromination of the double bond.
上記窒素塩基または他の塩基のパーブロマイド
のほかに、エーテル例えば殊にジオキサンのよう
な環式エーテルの臭素付加生成物を有利に使うこ
ともできる。この場合にも先に挙げたような第3
芳香族塩基を加えるのが有利である。 In addition to the perbromides of the above-mentioned nitrogen bases or other bases, it is also advantageous to use bromine addition products of ethers, such as cyclic ethers, such as in particular dioxane. In this case as well, the third
It is advantageous to add an aromatic base.
これらパーブロマイドまたは臭素付加物を不活
性有機溶媒例えば先に挙げた溶媒、さらにエーテ
ル、炭化水素、アルコール例えば殊に低級脂肪族
の1価または2価アルコール例えばメタノール、
エタノール、n―ブタノールまたはエチレングリ
コールの中で反応させる。 These perbromides or bromine adducts are dissolved in inert organic solvents, such as the solvents mentioned above, as well as ethers, hydrocarbons, alcohols, especially lower aliphatic mono- or dihydric alcohols, such as methanol,
React in ethanol, n-butanol or ethylene glycol.
上記臭素化合物のほかに他の臭素付加錯体例え
ばテトラメチルアンモニウムブロマイドの臭素付
加錯体も使うことができる。 In addition to the above-mentioned bromine compounds, other bromine addition complexes such as the bromine addition complex of tetramethylammonium bromide can also be used.
なお、ビリジンハイドロブロマイドパーブロマ
イドを使うのが非常に有利であつて、これをビリ
ジン溶液中で室温、低温または高温例えば−10〜
+100℃、好ましくは0〜20℃で反応させる。 Furthermore, it is very advantageous to use pyridine hydrobromide perbromide, which is prepared in a pyridine solution at room temperature, low temperature or high temperature, e.g.
The reaction is carried out at +100°C, preferably between 0 and 20°C.
こうして得た5,6―ジブロモ付加生成物を6
価クロム化合物例えば3酸化クロムまたはクロム
酸で酸化するには塩基性ないし中性の媒質中で行
うべきである。所望ならば、この酸化反応では、
上記の臭素化反応で使つた塩基例えばピリジンを
十分な量で加えて中和点を超えすぎないようにす
るか、または前段階で得た臭素化反応混合物をピ
リジンクロム酸溶液と混合する。この反応操作を
約−10〜+30℃で行うのが有利である。 The 5,6-dibromo addition product thus obtained was
Oxidation with valent chromium compounds such as chromium trioxide or chromic acid should be carried out in a basic to neutral medium. If desired, in this oxidation reaction,
Either the base used in the above bromination reaction, such as pyridine, is added in a sufficient amount so as not to exceed the neutralization point too much, or the bromination reaction mixture obtained in the previous step is mixed with the pyridine chromate solution. Advantageously, this reaction operation is carried out at a temperature of about -10 DEG to +30 DEG C.
こうして得たクロム酸酸化反応生成物から臭化
水素を脱離するには同じくそれ自体公知の方法に
よつて行うことができる。例えばリチウム塩殊に
ハロゲン化リチウム主として臭化リチウムのよう
な無機塩基性剤をアルカリ金属やアルカリ土類金
属の塩基性塩例えばリチウム、ナトリウム、カル
シウムまたはマグネシウムの炭酸塩または塩基性
炭酸塩の存在の下で使う。この方法では溶媒とし
て有利には低級脂肪族カルボン酸のジアルキルア
ミド殊にジメチルホルムアミドのような低級アル
キル誘導体を0〜約180℃、有利には80〜150℃で
使う。この臭化水素脱離反応に、先に挙げたよう
な芳香族性の窒素含有塩基殊にピリジンまたはコ
リジンを使うこともできる。 Hydrogen bromide can be removed from the chromic acid oxidation reaction product thus obtained by a method known per se. Inorganic basic agents such as lithium salts, especially lithium halides, primarily lithium bromide, and basic salts of alkali metals or alkaline earth metals, such as lithium, sodium, calcium or magnesium carbonates or in the presence of basic carbonates, Use below. In this process, preferably a lower alkyl derivative such as a dialkylamide of a lower aliphatic carboxylic acid, especially dimethylformamide, is used as a solvent at a temperature of from 0 to about 180°C, preferably from 80 to 150°C. For this hydrogen bromide elimination reaction, it is also possible to use aromatic nitrogen-containing bases such as those mentioned above, especially pyridine or collidine.
こうして臭化水素を脱離すれば、反応生成物と
して、17α―プロピオン酸アルデヒド―アセター
ル側鎖をもつ4,6―ジエン―3―オン誘導体が
生成する。 When hydrogen bromide is eliminated in this way, a 4,6-dien-3-one derivative having a 17α-propionic aldehyde-acetal side chain is produced as a reaction product.
第二の場合には、臭化水素の脱離によつて得ら
れた4,6―ジエン誘導体にチオアルカン酸をそ
れ自体公知の方法によつて、すなわち式()に
おけるR1とR2とがさらに6,7―C・C結合を
表わす化合物に対して知られている方法によつて
付加し、以下に示す如くそして次にまたはこの付
加と同時に酸性溶液中で6価クロム化合物で処理
するのである。 In the second case, a thioalkanoic acid is added to the 4,6-diene derivative obtained by elimination of hydrogen bromide by a method known per se, that is, R 1 and R 2 in formula () are Furthermore, it is added by known methods to compounds exhibiting 6,7-C.C bonds and treated with a hexavalent chromium compound in an acidic solution as shown below and then or simultaneously with this addition. be.
この4,6―ジエン誘導体へのチオカルボン酸
の付加反応を上記の意味でのそれ自体公知の方法
によつて、例えば当該ステロイドを溶媒なしで過
剰のチオカルボン酸で熱時に処理するようにして
行うことができる。しかし、この4,6―ステロ
イドジエンを極性溶媒殊にアルコール、主として
炭素原子1〜7個をもつ低級アルカノール中で、
所望ならば水を加えて、チオカルボン酸約1.5〜
3.5モルと反応させると、より高い収率が達せら
れる。最高収率は〜約120℃、例えば上記アルコ
ール例えばメタノール、エタノール、プロパノー
ル、イソプロパノール、ブタノールまたはペンタ
ノールの沸点で水の不在の下で反応させる場合に
達せられる。その温度が50〜100℃であるのが最
も好ましい。この方法によつて所望の7α―アシ
ルチオ誘導体が、その7β―異性体を有意に生成
することなく、非常に高い収率で得られる。チオ
カルボン酸としては、殊にC―原子1〜7個をも
つ低級チオアルカン酸、例えばチオ酢酸、チオプ
ロピオン酸またはチオ吉草酸を使う。 The addition reaction of the thiocarboxylic acid to the 4,6-diene derivative is carried out in the above sense by a method known per se, for example by treating the steroid without a solvent with an excess of the thiocarboxylic acid at the time of heating. I can do it. However, when this 4,6-steroid diene is dissolved in a polar solvent, especially an alcohol, mainly a lower alkanol having 1 to 7 carbon atoms,
Add water if desired to obtain approximately 1.5 to 1.5 thiocarboxylic acids.
Higher yields are achieved when reacting with 3.5 mol. The highest yields are achieved when reacting in the absence of water at ~120° C., for example the boiling point of the abovementioned alcohols such as methanol, ethanol, propanol, isopropanol, butanol or pentanol. Most preferably, the temperature is between 50 and 100°C. By this method the desired 7α-acylthio derivatives are obtained in very high yields without significant formation of its 7β-isomer. The thiocarboxylic acids used are in particular lower thioalkanoic acids having 1 to 7 C atoms, such as thioacetic acid, thiopropionic acid or thiovaleric acid.
原料として使うアセタールは任意の脂肪族、脂
環式、芳香脂肪族または脂肪―脂環式のアルコー
ル、主としてC―原子1〜7個をもつ低級アルカ
ノールまたはC―原子1〜7個をもつ低級アルカ
ンジオールから導かれたものである。殊に3β,
17β―ジヒドロキシ―17α―プレグナン―5―エ
ン―21―アルビテドのエチレングリコールアセタ
ールを原料として使う。 The acetal used as raw material can be any aliphatic, cycloaliphatic, araliphatic or alicyclic aliphatic alcohol, mainly lower alkanols with 1 to 7 C atoms or lower alkanes with 1 to 7 C atoms. It is derived from diol. Especially 3β,
Ethylene glycol acetal of 17β-dihydroxy-17α-pregnane-5-ene-21-albitedo is used as a raw material.
得られた7α―アシルチオ誘導体を、酸性溶液
中、特に鉱酸溶液中6価クロム化合物で処理す
る。このような処理中、アルデヒド―アセタール
基は同時に脱アセタール化され、しかる後環状ヘ
ミーアセタールを得るための17β―ヒドロキシ基
によるプロピオンアルデヒド側鎖の環化並びに対
応するラクトン基を得るためのその酸化が生起す
る。酸化は、酸性溶液中、特に塩酸又は一種のリ
ン酸中、又は1〜7個の炭素原子を有するアルカ
ンカルボン酸の如き低級カルボン酸、例えばギ
酸、酢酸又はプロピオン酸又は酪酸もしくは吉草
酸の一種中、又はこれらの酸の混合物中で、更に
水の添加と共にもしくは添加なしで三酸化クロム
を用いて行うことができる。酸化は又、ケトンも
しくはエーテルの如き有機溶剤、例えばアセト
ン、ジオキサンもしくはテトラヒドロフラン中、
水の添加と共にもしくは添加なしで行うこともで
きる。 The 7α-acylthio derivative obtained is treated with a hexavalent chromium compound in an acidic solution, in particular a mineral acid solution. During such treatment, the aldehyde-acetal group is simultaneously deacetalized, followed by cyclization of the propionaldehyde side chain with the 17β-hydroxy group to obtain the cyclic hemyacetal and its oxidation to obtain the corresponding lactone group. occurs. The oxidation is carried out in an acidic solution, in particular in hydrochloric acid or one of the phosphoric acids, or in a lower carboxylic acid such as an alkanecarboxylic acid having 1 to 7 carbon atoms, such as formic acid, acetic acid or propionic acid or one of butyric acid or valeric acid. or with chromium trioxide in a mixture of these acids, with or without further addition of water. Oxidation can also be carried out in organic solvents such as ketones or ethers, such as acetone, dioxane or tetrahydrofuran.
It can also be carried out with or without the addition of water.
環状ヘミーアセタールを最初に得る場合、酸化
前に揚げた酸の一種を用いて予め処理し、次いで
第二の工程において丁度述べた条件のもとで酸化
を行うことが有利である。 If the cyclic hemyacetal is first obtained, it is advantageous to pre-treat it with one of the fried acids before oxidation and then carry out the oxidation in a second step under the conditions just mentioned.
次に本発明方法を、スピロノラクトンの製造を
例にして次の工程図によつて説明することができ
る。この工程図には原料(′)に基ずいた理論
収量に対する収率も併記してある。明らかなよう
に、原料(′)に関するスピロノラクトン′の
全収量は理論の47%である。 Next, the method of the present invention can be explained using the following process diagram using the production of spironolactone as an example. This process diagram also shows the yield relative to the theoretical yield based on the raw material ('). As can be seen, the total yield of spironolactone' with respect to raw material (') is 47% of theory.
従来の方法例えば前記ドイツ特許公開明細書記
載の方法と比較するには、デヒドロ―エピ―アン
ドロステロンからの(′)の製造、すなわちち
デヒドロ―エピ―アンドロステロンをリチウムの
存在下でクロロプロピオンアルデヒド―アセター
ル例えばエチレンアセタールと反応させるそれら
特許明細書で採用されている(′)の製造を含
めねばならない。この工程は理論の約60%の収率
で進む。全収量をデヒドロ―エピ―アンドロステ
ロンに関して重量%に換算すれば、本発明方法に
よるスピロノラクトンの製造では例えば後記実施
例2および7におけるように収率は約41重量%で
ある。これに反して、先に述べたように、前記の
方法(C)〜(E)による収率は、デヒドロ―エピ―アン
ドロステロンに関してスピロノラクトン約10〜23
重量%である。 For comparison with conventional methods, such as those described in the above-mentioned German patent application, the preparation of (') from dehydro-epi-androsterone, i.e. dehydro-epi-androsterone is converted into chloropropionaldehyde in the presence of lithium. - must include the preparation of (') adopted in those patent specifications by reacting with an acetal, for example ethylene acetal. The process proceeds with a yield of approximately 60% of theory. If the total yield is converted to % by weight with respect to dehydro-epi-androsterone, then in the preparation of spironolactone according to the process of the invention, as for example in Examples 2 and 7 below, the yield is about 41% by weight. In contrast, as mentioned above, the yields according to methods (C) to (E) above are approximately 10-23% of spironolactone with respect to dehydro-epi-androsterone.
Weight%.
従つて、化合物(′)をデヒドロ―エピ―ア
ンドロステロンからLiの存在下でクロロプロピオ
ンアルデヒド―エチレンアセタールの付加によつ
て製造する限り、そしてこの場合に次に記載する
新らしい方法(これは本発明方法の特殊な実施形
式として本発明の範囲に包含される)を採用する
場合には、本発明方法は所望の最終生成物をなお
一層高い収率で与えることができる。すなわち、
本発明者は、デヒドロ―エピ―アンドロステロン
をリチウムの存在下でクロロプロピオンアルデヒ
ドアセタールと反応させた場合に、この反応に引
続いて反応生成物をそれ自体公知の方法により水
蒸気処理すれば、多量のデヒドロ―エピ―アンド
ロステトロンを回収できることを見出した。デヒ
ドロ―エピ―アンドロステロンと反応生成物例え
ば17α―(3′―エチレンジオキシ―プロピル)―
アンドロスト―5―エン―3β,17―ジオールと
は、通常の精製操作例えばクロマトグラフイ(例
えば酸化アルミニウム)および(または)結晶化
によつて水蒸気中で蒸発しない成分からそれぞれ
互いに容易に分離することができる。出発材料を
得る点に関する本発明の前記改良によつて、本明
細書の後記例5でも説明するとおり、例えばスピ
ロノラクトンの収量を、出発材料の回収の結果例
えばデヒドロ―エピ―アンドロステロンの回収の
結果反応したデヒドロ―エピ―アンドロステンの
50重量%に増やすことができる。 Therefore, insofar as compound (') is prepared from dehydro-epi-androsterone by addition of chloropropionaldehyde-ethylene acetal in the presence of Li, and in this case the new method described below, which is If a special embodiment of the inventive process is employed (which is included within the scope of the invention), the inventive process can give the desired end product in even higher yields. That is,
The inventor has discovered that when dehydro-epi-androsterone is reacted with chloropropionaldehyde acetal in the presence of lithium, if this reaction is followed by steam treatment of the reaction product by methods known per se, a large amount of It was discovered that dehydro-epi-androstetron could be recovered. Dehydro-epi-androsterone and reaction products such as 17α-(3′-ethylenedioxy-propyl)-
Androst-5-ene-3β,17-diols are easily separated from each other from components that do not evaporate in water vapor by conventional purification procedures such as chromatography (e.g. aluminum oxide) and/or crystallization. be able to. The improvements of the present invention with respect to obtaining starting materials, as also explained in Example 5 hereinafter, reduce the yield of, for example, spironolactone as a result of the recovery of the starting material, for example as a result of the recovery of dehydro-epi-androsterone. of the reacted dehydro-ep-androstene.
Can be increased to 50% by weight.
本発明方法の特に優れた有利な点は、出発材料
と臭素化剤との反応工程、それらの酸化工程およ
び脱臭化水素工程において、4,6―ジエン―3
―オン中間生成物が例えば簡単な結晶化によつて
容易に精製できる単位化合物として形成される点
にもある。これに対して式()による4,6―
ジエン―3―オン工程を経由する前記の方法(C)〜
(E)では、生成物が常に21a―炭素原子でのエピマ
ーであるアルコキシ化合物の混合物であるため
に、前記構成の純粋な組成物を得ることは難かし
い。その結果、最終工程の精製例えばスピロノラ
クトンの精製は他の事柄に比べて極めて退屈で複
雑になる。これに対して本発明方法の最終工程で
は前記品質の生成物が得られる。その最終工程は
通常簡単な精製例えば結晶化であり、完全に純粋
な生成物が得られる。 A particular advantage of the process according to the invention is that in the reaction step of the starting materials with the brominating agent, their oxidation step and dehydrobromination step, 4,6-diene-3
It is also the case that the -one intermediate products are formed as unitary compounds that can be easily purified, for example by simple crystallization. On the other hand, 4,6- by formula ()
The above method (C) via the diene-3-one step
In (E), it is difficult to obtain a pure composition of the above structure, since the product is always a mixture of alkoxy compounds that are epimers at the 21a-carbon atom. As a result, the final step purification, for example the purification of spironolactone, is extremely tedious and complex compared to other matters. In contrast, in the final step of the process according to the invention, a product of said quality is obtained. The final step is usually a simple purification, such as crystallization, to obtain a completely pure product.
さらに、本発明方法は前記方法(B)すなわち米国
特許第3738983号および第3270008号明細書記載の
方法に比較して、先に述べた収率に関する利点の
ほかに、操作段階が少くて技術的に簡単であるこ
とに利点がある。 Furthermore, the method of the present invention has fewer operational steps and is less technical than the aforementioned method (B), that is, the method described in U.S. Pat. It has the advantage of being simple.
本発明は、任意の中間段階で得られる化合物か
ら出発して残りの工程段階を行うかまたはその工
程段階を行うかまたはその工程を任意段階で中断
するか、または原料をその反応の場で生成させる
ような実施形式にも係わるものである。さらに、
本発明は、デヒドロ―エピ―アンドロステロンを
リチウムの存在下でクロロプロピオンアルデヒド
アセタールと反応させて原料を製造しそしてこの
反応の後で反応混合物を予じめ水蒸気処理した後
に未反応のデヒドロ―エピ―アンドロステロンを
回収することから成る前記の特殊な実施形式にも
係わるものである。 The present invention allows starting from the compound obtained at any intermediate step to carry out the remaining process steps, or to carry out the process step or to interrupt the process at any stage, or to produce the raw materials in situ in the reaction. It also concerns the implementation format that allows moreover,
The present invention involves reacting dehydro-epi-androsterone with chloropropionaldehyde acetal in the presence of lithium to produce the raw material and after this reaction, pre-steaming the reaction mixture before unreacted dehydro-epi-androsterone. - also relates to the above-mentioned special embodiment, which consists in recovering androsterone.
次に実施例によつて本発明をさらに具体的に説
明する。 Next, the present invention will be explained in more detail with reference to Examples.
例 1
デヒドロ―エピ―アンドロステロン20gを無水
テトラヒドロフラン500mlに溶かす。これに小片
に切つたリチウム線5.2gを加える。次に氷浴で
0℃に冷却しそしてN2ガス中でかきまぜながら
無水テトラヒドロフラン50mlに溶かしたβ―クロ
ロプロピオンアルデヒド―エチレンアセタール38
gの溶液を15分間で滴加する。この際、反応温度
が10℃以上に上昇しないように強冷(氷・食塩混
合物を使う)する。これをさらに0℃で2.5時間
そして室温で夜通しかきまぜる(窒素ガス中で行
う)。次に余分のリチウム片を分離して反応溶液
を氷水に注ぎ入れる。これを酢酸エステルで抽出
しそしてNaClの飽和水溶液で中性になるまで洗
う。有機相をNa2SO4で乾かしそして蒸発し、析
出した粗生成物を活性度の中性Al2O3の300g
でろ過する。この際、石油エーテルとトルエンと
の1:1の混合物3を使つて未反応の反応剤お
よび非ステロイド性不純物を前以つて溶離する。
次に溶離剤としてCH2Cl2を使えば17α―(3′―エ
チレンジオキシ―プロピル)―アンドロスト―5
―エン―3β,17β―ジオール19.9gが得られる。
このものはアセトン・石油エーテル混合物から結
晶化の後に181〜182℃で融解する。収量16.4g
(理論の60.6%)。IR:3600,3450cm-1(CH2Cl2)。
NMR:0.87,s,CH3(18);1.02,s,CH3
(19);3.50,m,CH(3);3.92,m,―
OCH2CH2O―;4.91,t,J=4,CH(3′);
5.34,m,CH(6)(CDCl3)。Example 1 Dissolve 20g of dehydro-epi-androsterone in 500ml of anhydrous tetrahydrofuran. Add 5.2 g of lithium wire cut into small pieces to this. β-Chloropropionaldehyde-ethylene acetal 38 was then cooled to 0 °C in an ice bath and dissolved in 50 ml of anhydrous tetrahydrofuran while stirring under N2 gas.
g solution is added dropwise over 15 minutes. At this time, strongly cool (using an ice/salt mixture) so that the reaction temperature does not rise above 10°C. This is stirred for a further 2.5 hours at 0° C. and overnight at room temperature (done under nitrogen gas). Next, excess lithium pieces are separated and the reaction solution is poured into ice water. This is extracted with acetic acid ester and washed with a saturated aqueous solution of NaCl until neutral. The organic phase was dried with Na 2 SO 4 and evaporated, the precipitated crude product was combined with 300 g of activity neutral Al 2 O 3
Filter. In this case, unreacted reactants and non-steroidal impurities are pre-eluted using a 1:1 mixture 3 of petroleum ether and toluene.
Next, using CH 2 Cl 2 as the eluent, 17α-(3′-ethylenedioxy-propyl)-androst-5
19.9 g of -ene-3β,17β-diol is obtained.
It melts at 181-182°C after crystallization from an acetone-petroleum ether mixture. Yield 16.4g
(60.6% of theory). IR: 3600, 3450 cm -1 (CH 2 Cl 2 ).
NMR: 0.87, s, CH 3 (18); 1.02, s, CH 3
(19);3.50,m,CH(3);3.92,m,-
OCH 2 CH 2 O―; 4.91, t, J=4, CH(3′);
5.34, m, CH(6) ( CDCl3 ).
例 2
17α―(3′―エチレンジオキシ―プロピル)―
アンドロスト―5―エン―3β,17β―ジオール6
gをピリジン60ml中に固体のピリジンハイドロブ
ロマイドパーブロマイド5.4gと0℃で混合する。
非水性条件下で0℃で3時間かきまぜる。反応開
始から1時間後に、H2O6mlに溶かしたCrO3の
4.5gを氷冷したピリジン45mlにかきまぜながら
滴加し、この際フラスコ内の温度が10℃以上に上
昇しないように滴加速度を調整する。こうして生
成したピリジンクロメート溶液を、これと平行に
進行する臭素化反応の終るまで0℃でかきまぜ
る。次にこのピリジンクロメート溶液を上記臭素
化反応溶液に注ぎ入れて、さらに0℃で3時間そ
して室温で夜通しかきまぜる。これを多量の
CHCl3で希釈し、NaClの飽和水溶液で4回、水
で10回そして再びNaClの飽和水溶液で4回洗う。
この有機相をNa2SO4で乾かしそして真空中で乾
くまで蒸発する。Example 2 17α-(3'-ethylenedioxy-propyl)-
Androst-5-ene-3β,17β-diol 6
g is mixed with 5.4 g of solid pyridine hydrobromide perbromide in 60 ml of pyridine at 0°C.
Stir for 3 hours at 0°C under non-aqueous conditions. One hour after the start of the reaction, CrO 3 dissolved in 6 ml of H 2 O was added.
Add 4.5 g dropwise to 45 ml of ice-cooled pyridine while stirring, adjusting the dropping speed so that the temperature inside the flask does not rise above 10°C. The pyridine chromate solution thus produced is stirred at 0° C. until the bromination reaction, which proceeds in parallel, is completed. This pyridine chromate solution is then poured into the bromination reaction solution and stirred for an additional 3 hours at 0°C and overnight at room temperature. A large amount of this
Dilute with CHCl 3 and wash 4 times with a saturated aqueous solution of NaCl, 10 times with water and again 4 times with a saturated aqueous solution of NaCl.
The organic phase is dried with Na 2 SO 4 and evaporated to dryness in vacuo.
こうして析出した粗製の酸化生成物を、これか
ら残余のピリジンを共沸的に除去するために、ト
ルエンに溶かして真空蒸発する操作を繰返し行
う。これを無水ジメチルホルムアミド108mlに溶
かし、LiBrおよびLi2CO3の各10.8gつづを加え
そしてN2ガス中でかきまぜながら15分間で100℃
に加熱しそしてこの温度でさらに1時間15分放置
する。その後で放冷し、酢酸エステルで希釈し、
水で10回そして飽和食塩水で1回洗う。有機相を
Na2SO4で乾かし、真空中で蒸発し、その蒸発残
分を中性Al2O3(活性度)100gでろ過する。こ
れを先ずトルエン500mlで非極性の不純物を溶離
する。次に酢酸エステルで溶離したものは17β―
ヒドロキシ―17α―(3′―エチレンジオキシ―プ
ロピル)―アンドロスタ―4,6―ジエン―3―
オン4.56gから成る。このものはアセトン・石油
エーテル混合物から1回再結晶の後に132℃で融
解する。再結晶後の収量は4.44g(理論の74.7
%)である。 The crude oxidation product thus precipitated is repeatedly dissolved in toluene and evaporated in vacuum in order to azeotropically remove residual pyridine. Dissolve this in 108 ml of anhydrous dimethylformamide, add 10.8 g each of LiBr and Li 2 CO 3 and heat to 100 °C for 15 minutes while stirring in N 2 gas.
and leave at this temperature for a further 1 hour and 15 minutes. After that, let it cool and dilute with acetate,
Wash 10 times with water and once with saturated saline. organic phase
Dry with Na 2 SO 4 , evaporate in vacuo and filter the evaporation residue through 100 g of neutral Al 2 O 3 (activity). First, non-polar impurities are eluted with 500 ml of toluene. Next, what was eluted with acetate was 17β-
Hydroxy-17α-(3'-ethylenedioxy-propyl)-androster-4,6-diene-3-
Consisting of 4.56g of onion. It melts at 132°C after one recrystallization from an acetone/petroleum ether mixture. The yield after recrystallization was 4.44 g (theoretical 74.7
%).
IR:3570,3450,1655,1620,1582cm-1
(CH2Cl2)。UV:287(19700)(C2H5OH溶液)。
NMR:0.95,s,CH3(18);1.10,s,CH3
(19);約3.95,m,―OCH2CH2O―;4.89,t,
J=4,CH(3′);5.65,s,CH(4);6.08,s
(2H),CH(6)+CH(7)(CDCl3)。〔α〕D=−6゜
(1.04,CHCl3)。 IR: 3570, 3450, 1655 , 1620, 1582cm -1
( CH2Cl2 ). UV: 287 (19700) ( C2H5OH solution ).
NMR: 0.95, s, CH 3 (18); 1.10, s, CH 3
(19); Approximately 3.95, m, ―OCH 2 CH 2 O―; 4.89, t,
J=4, CH(3′); 5.65, s, CH(4); 6.08, s
(2H), CH(6) + CH(7) (CDCl 3 ). [α] D = −6° (1.04, CHCl 3 ).
例 3
17β―ヒドロキシ―17α―(3′―エチレンジオキ
シ―プロピル)―アンドロスタ―4,6―ジエン
―3―オン5gを室温でメタノール50mlに溶か
す。これに水7.5mlおよびチオ酢酸2.5mlを加えて
室温で3時間かきまぜる。これをNaHCO3の2N
の氷冷した水溶液に注ぎ入れ、酢酸エステルで抽
出しそしてNaClの飽和水溶液で中性になるまで
洗う。乾かし(Na2SO4)そして真空中で蒸発す
れば、7α―アセチルチオ―17β―ヒドロキシ―
17α―(3′―エチレンジオキシ―プロピル―アン
ドロスト―4―エン―3―オン5.86gが得られ
る。〔IR:3450(巾広い)、1685,1670,1620cm-1
(CH2Cl2)。NMR:0.92,s,CH3(18);1.22,
s,CH3(19):2.33,s,SCOCH3;3.94,m,
CH(7)+―OCH2CH2O―;4.91,t,J=4,
CH(3′);5.68,bs,CH(4)(CDCl3)〕。このもの
をそのまま処理する。この粗生成物5.86gをアセ
トン200mlに溶かしそして0℃に冷却する。これ
に8NのH2SO4に溶かした8NのCrO3溶液10mlを
温度が10℃を超えないようにかきまぜながら滴加
する。次に室温で45分間かきまぜる。さらに上記
のCrO3溶液5mlを室温で滴加して室温でさらに
1時間かきまぜる。これにメタノール10mlを加え
てさらに10分間かきまぜてから酢酸エステルで希
釈する。酢酸エステル相を酢酸ナトリウムおよび
食塩の飽和水溶液でそれぞれ3回洗い、Na2SO4
で乾かしそして真空中で乾くまで蒸発する。こう
して結晶性の粗成成物5.5gが得られる。これら
をメタノールから−10℃で結晶化した後に複融点
135℃および202℃をもつスピロノラクトン(7α
―アセチルチオ―3―オキソ―17α―プレグナン
―4―エン―21,17―カルボラクトン)2.75g
(例3の生成物に基ずいた理論の51%)が得られ
る。IR:1770,1670〜1700(広巾),1620cm-1
(CH2Cl2)。UV:240(19400)(C2H5OH溶液)、
NMR;0.97,s,CH3(18);1.20,s,CH3
(19);2.31,s,SCOCH3;2.84,8本シグナ
ル、J6.6=15,J6.7=4,J4.6=2,CH(6β);
3.97,m,CH(7);5.68,d,J=2,CH(4)
(CDCl3)。Example 3 Dissolve 5 g of 17β-hydroxy-17α-(3'-ethylenedioxy-propyl)-androster-4,6-dien-3-one in 50 ml of methanol at room temperature. Add 7.5 ml of water and 2.5 ml of thioacetic acid to this and stir at room temperature for 3 hours. Add this to 2N of NaHCO3
Pour into an ice-cold aqueous solution of water, extract with acetic acid ester and wash with a saturated aqueous solution of NaCl until neutral. Drying (Na 2 SO 4 ) and evaporation in vacuo yields 7α-acetylthio-17β-hydroxy-
5.86 g of 17α-(3'-ethylenedioxy-propyl-androst-4-en-3-one is obtained. [IR: 3450 (wide), 1685, 1670, 1620 cm -1
( CH2Cl2 ). NMR: 0.92, s, CH 3 (18); 1.22,
s, CH 3 (19): 2.33, s, SCOCH 3 ; 3.94, m,
CH(7)+―OCH 2 CH 2 O―; 4.91, t, J=4,
CH(3′); 5.68, bs, CH(4)(CDCl 3 )]. Process this as is. 5.86 g of this crude product are dissolved in 200 ml of acetone and cooled to 0°C. To this, 10 ml of 8N CrO 3 solution in 8N H 2 SO 4 is added dropwise with stirring so that the temperature does not exceed 10°C. Then stir at room temperature for 45 minutes. Furthermore, 5 ml of the above CrO 3 solution was added dropwise at room temperature, and the mixture was further stirred at room temperature for 1 hour. Add 10 ml of methanol to this, stir for another 10 minutes, and then dilute with acetate. The acetate ester phase was washed three times each with saturated aqueous solutions of sodium acetate and common salt, Na 2 SO 4
and evaporate in vacuo until dry. 5.5 g of a crystalline crude product are thus obtained. After crystallizing these from methanol at -10℃, the compound melting point
Spironolactone (7α) with 135℃ and 202℃
-Acetylthio-3-oxo-17α-pregnane-4-ene-21,17-carboractone) 2.75g
(51% of theory based on the product of Example 3) is obtained. IR: 1770, 1670~1700 (wide width), 1620cm -1
( CH2Cl2 ). UV: 240 (19400) ( C2H5OH solution ),
NMR; 0.97, s, CH 3 (18); 1.20, s, CH 3
(19); 2.31, s, SCOCH 3 ; 2.84, 8 signals, J 6.6 = 15, J 6.7 = 4, J 4.6 = 2, CH (6β);
3.97, m, CH(7); 5.68, d, J=2, CH(4)
( CDCl3 ).
例 4
17β―ヒドロキシ―17α―(3′―エチレンジオキ
シ―プロピル)―アンドロスタ―4,6―ジエン
―3―オン1.80gを沸騰メタノール5.1mlに溶か
す。この沸騰溶液にチオ酢酸1mlを5分間で滴加
しそしてさらに30分間煮沸する。これを冷却し、
酢酸エステルで希釈しそしてNaHCO3の水溶液
で洗つてからNaClの水溶液で中性点になるまで
洗う。その有機相をNa2SO4で乾かしてから真空
中で蒸発する。こうして粗生成物2.09gが得られ
る。これをアセトン80mlに溶かし、0℃で8N硫
酸中の8NCrO3溶液4mlをかきまぜながら加え
る。これを室温で1時間かきまぜ、さらに上記
CrO3溶液2mlを加えてさらに1時間かきまぜる。
次に酢酸エステル中に採取し、酢酸ナトリウムお
よびNaClの飽和水溶液でそれぞれ3回洗い、
Na2SO4で乾かしそして真空中で乾くまで蒸発す
る。こうしてスピロノラクトン1.87gが得られ
る。CH2Cl2・メタノール混合物から1回再結晶
すれば、純粋な化合物1.25gが得られる。(物理
的データは例3に記載のものと同じである)。Example 4 Dissolve 1.80 g of 17β-hydroxy-17α-(3'-ethylenedioxy-propyl)-androster-4,6-dien-3-one in 5.1 ml of boiling methanol. To this boiling solution 1 ml of thioacetic acid is added dropwise over 5 minutes and boiled for a further 30 minutes. Cool this and
Dilute with acetate and wash with an aqueous solution of NaHCO 3 and then with an aqueous solution of NaCl until neutral point. The organic phase is dried with Na 2 SO 4 and then evaporated in vacuo. 2.09 g of crude product are thus obtained. This is dissolved in 80 ml of acetone and at 0° C. 4 ml of a solution of 8NCrO 3 in 8N sulfuric acid is added with stirring. Stir this at room temperature for 1 hour, and then
Add 2 ml of CrO 3 solution and stir for an additional hour.
It was then taken up in acetic acid ester, washed three times each with saturated aqueous solutions of sodium acetate and NaCl,
Dry with Na 2 SO 4 and evaporate to dryness in vacuo. 1.87 g of spironolactone are thus obtained. One recrystallization from a CH 2 Cl 2 -methanol mixture gives 1.25 g of pure compound. (Physical data are the same as described in Example 3).
例 5
デヒドロ―エピ―アンドロステロン20gを無水
テトラヒドロフラン500mlに溶かす。これに小片
に切つたリチウム線5.2gを加える。次に氷浴で
0℃で冷却しそしてN2ガス中でかきまぜながら
無水テトラヒドロフラン50mlに溶かしたβ―クロ
ロプロピオンアルデヒド―エチレンアセタール38
gの溶液を15分間で滴加する。この際、反応温度
が10℃以上に上昇しないように強冷(氷・食塩混
合物を使う)する。これをさらに0℃で2.5時間
そして室温で夜通しかきまぜる(窒素ガス中で行
う)。次に余分のリチウム片を分離して氷水に注
ぎ入れそして余分の反応体および分解生成物を水
蒸気蒸留によつて除く。水蒸気蒸留されない残分
を塩化メチレンで抽出する。この塩化メチレン相
をNaClの飽和水溶液で中性になるまで洗い、
Na2SO4で乾かしそして真空中で蒸発する。こう
して析出した粗生成物を活性度の中性Al2O3の
600g上でろ過する。先ず塩化メチレン1づつ
で4区劃を溶離する。次にこのカラムを塩化メチ
レンと酢酸エステルとの4:1の混合物で6区劃
(いずれも1)を溶離する。3番目の区劃を蒸
発すれば未反応の粗製デヒドロ―エピ―アンドロ
ステロン3.2gが得られ、これをアセトン―石油
エーテル混合物から再結晶すれば純物質2.65gが
回収される。区劃4〜10から17α―(3―エチレ
ンジオキシ―プロピル)―アンドロスト―5―エ
ン―3β,17β―ジオール20.1gが生成する。これ
は塩化メチレン・石油エーテル混合物から結晶化
した後に181〜182℃で融解する。収量は17g(回
収原料を考慮して理論の74%)である。Example 5 Dissolve 20g of dehydro-epi-androsterone in 500ml of anhydrous tetrahydrofuran. Add 5.2 g of lithium wire cut into small pieces to this. β-Chloropropionaldehyde-ethylene acetal 38 was then cooled to 0 °C in an ice bath and dissolved in 50 ml of anhydrous tetrahydrofuran while stirring under N2 gas.
g solution is added dropwise over 15 minutes. At this time, strongly cool (using an ice/salt mixture) so that the reaction temperature does not rise above 10°C. This is stirred for a further 2.5 hours at 0° C. and overnight at room temperature (done under nitrogen gas). The excess lithium pieces are then separated and poured into ice water and the excess reactants and decomposition products are removed by steam distillation. The residue that is not steam distilled is extracted with methylene chloride. The methylene chloride phase was washed with a saturated aqueous solution of NaCl until neutral;
Dry with Na 2 SO 4 and evaporate in vacuo. The crude product precipitated in this way was treated with neutral Al 2 O 3 of activity.
Filter over 600g. First, four sections were eluted with one portion of methylene chloride. The column is then eluted in six sections (all 1) with a 4:1 mixture of methylene chloride and acetic acid ester. Evaporation of the third section yields 3.2 g of unreacted crude dehydro-epi-androsterone, which is recrystallized from an acetone-petroleum ether mixture to recover 2.65 g of pure material. From sections 4 to 10, 20.1 g of 17α-(3-ethylenedioxy-propyl)-androst-5-ene-3β,17β-diol was produced. It melts at 181-182°C after crystallization from a methylene chloride/petroleum ether mixture. Yield is 17 g (74% of theory considering recovered material).
Claims (1)
水素原子である) で表わされる化合物の製造方法であつて、3β,
17―ジヒドロキシ―17α―プレグナン―5―エン
―21―アルデヒドのアセタールを塩基性ないし中
性の媒質中で2重結合への臭素付加に適する臭素
化剤で処理し、こうして得た5,6―ジブロモ化
合物を塩基性ないし中性の条件の下で6価クロム
化合物で酸化し、得られた生成物を、7α―アシ
ルチオ基に相当するチオカルボン酸で予め処理し
た後、酸性溶液中6価クロム化合物で処理するこ
とを含んでなる、前記方法。 2 アシルチオ基R1として炭素原子1〜7個を
もつ低級チオアルカデ酸から導かれた基をもつ化
合物を製造する特許請求の範囲第1項記載の方
法。 3 アシルチオ基R1としてアセチルチオ基をも
つ化合物を製造する特許請求の範囲第1項記載の
方法。 4 原料として、炭素原子1〜7個をもつ低級脂
肪族アルカノールから導かれたアセタールを使用
する特許請求の範囲第1〜3項のいずれかに記載
の方法。 5 原料として、炭素原子1〜7個をもつ低級ア
ルカンジオールから導かれたアセタールを使う特
許請求の範囲1〜3項のいずれかに記載の方法。 6 原料として、3β,17β―ジヒドロキシ―17α
―プレグナン―5―エン―21―アルデヒドのエチ
レングリコールアセタールを使う特許請求の範囲
第1〜3項のいずれかに記載の方法。 7 臭素化剤として、芳香族第3窒素塩基中で臭
素を使う特許請求の範囲第1〜6項のいずれかに
記載の方法。 8 臭素化剤として、芳香族第3窒素塩基の過臭
素化物またはそのハロゲン化水素酸塩、あるいは
エーテルの臭素付加生成物を使う特許請求の範囲
第1〜6項のいずれかに記載の方法。 9 塩素化された低級脂肪族炭化水素、エーテ
ル、ケトン、ジ低級アルキル―低級アルカン酸ア
ミドの中で所望ならば有機または無機塩基のよう
な緩衝剤の存在の下でまたは第3有機芳香族塩基
の中で臭素化する特許請求の範囲第8項記載の方
法。 10 ピリジン臭化水素酸塩過臭素化物をピリジ
ン中で使う特許請求の範囲第1〜9項のいずれか
に記載の方法。 11 低温または室温で反応させる特許請求の範
囲第1〜10項のいずれかに記載の方法。 12 0〜+20℃で臭素化する特許請求の範囲第
10項又は第11項記載の方法。 13 5,6―ジプロモー付加生成物を3酸化ク
ロムでまたは芳香族第3窒素塩基中でクロム酸で
酸化する特許請求の範囲第1〜12項のいずれか
に記載の方法。 14 臭素化において使つた塩基中で、酸化する
特許請求の範囲第13項記載の方法。 15 −10〜約+30℃で酸化する特許請求の範囲
第13項又は14項記載の方法。 16 塩基としてピリジンを使う特許請求の範囲
第14項または第15項に記載の方法。 17 クロム酸酸化生成物を無機塩基性剤で処理
して臭化水素を脱離する特許請求の範囲第1〜1
5項のいずれかに記載の方法。 18 ハロゲン化リチウムをアルカリ金属または
アルカリ土類金属の塩基性塩の存在下で使う特許
請求の範囲第17項記載の方法。 19 臭化リチウムを炭酸リチウムの存在下で使
う特許請求の範囲第18項記載の方法。 20 低級脂肪族カルボン酸のジアルキルアミド
の中で臭化水素を脱離する特許請求の範囲第18
項第19項記載の方法。 21 ジメチルホルムアミドを使う特許請求の範
囲第20項記載の方法。 22 80〜150℃で反応させる特許請求の範囲第
19〜21項のいずれかに記載の方法。 23 窒素含有芳香族塩基を使つて臭化水素を脱
離する特許請求の範囲第1〜15項のいずれかに
記載の方法。 24 式()におけるR1とR2とがその両方で
6,7―C・C結合を表わす化合物からR1がア
シルチオ基であつてR2が水素原子である式()
の化合物を製造するための公知の方法によつて、
17α―プロピオンアルビテド―アセタール側鎖を
もつ4,6―ジエン―3―オン誘導体をチオカル
ボン酸で処理する特許請求の範囲第1〜23項の
いずれかに記載の方法。 25 炭素原子1〜7個をもつ低級アルカノール
中で0〜120℃でチオカルボン酸約1.5〜3.5モル
を使つて処理する特許請求の範囲第24項記載の
方法。 26 無水アルコール中で50〜100℃で操作する
特許請求の範囲第24項記載の方法。 27 炭素原子1〜7個をもつ低級チオカルボン
酸と反応させる特許請求の範囲第24〜26項の
いずれかに記載の方法。 28 チオ酢酸と反応させる特許請求の範囲第2
7項記載の方法。 29 前項24〜28に記載のいずれかの方法に
より得られた化合物を、鉱酸溶液中6価クロムの
化合物で処理する特許請求の範囲第24〜28項
のいずれかに記載の方法。 30 前記酸化を、アセトンの添加と共に又は添
加せず、硫酸溶液中6価クロムを用いて行う特許
請求の範囲第29項記載の方法。 31 前記24〜28のいずれかの方法により得
られた化合物の酸化を、炭素原子1〜7個を有す
る低級カルボン酸中三酸化クロムで行う、特許請
求の範囲第24〜28項のいずれかに記載の方
法。[Claims] Primary formula: (In the formula, R 1 is an α-acylthio group and R 2 is a hydrogen atom.) A method for producing a compound represented by 3β,
The acetal of 17-dihydroxy-17α-pregnane-5-ene-21-aldehyde is treated with a brominating agent suitable for the addition of bromine to the double bond in a basic to neutral medium to give the 5,6- A dibromo compound is oxidized with a hexavalent chromium compound under basic to neutral conditions, and the resulting product is pretreated with a thiocarboxylic acid corresponding to a 7α-acylthio group, and then the hexavalent chromium compound is oxidized in an acidic solution. said method comprising treating with. 2. The method according to claim 1 for producing a compound having a group derived from a lower thioalkadic acid having 1 to 7 carbon atoms as the acylthio group R 1 . 3. The method according to claim 1 for producing a compound having an acetylthio group as the acylthio group R 1 . 4. The method according to any one of claims 1 to 3, wherein an acetal derived from a lower aliphatic alkanol having 1 to 7 carbon atoms is used as a raw material. 5. The method according to any one of claims 1 to 3, wherein an acetal derived from a lower alkanediol having 1 to 7 carbon atoms is used as a raw material. 6 As a raw material, 3β,17β-dihydroxy-17α
The method according to any one of claims 1 to 3, wherein ethylene glycol acetal of pregnane-5-ene-21-aldehyde is used. 7. The method according to any of claims 1 to 6, wherein bromine is used as the brominating agent in an aromatic tertiary nitrogen base. 8. The method according to any one of claims 1 to 6, wherein a perbrominated product of an aromatic tertiary nitrogen base or a hydrohalide thereof, or a bromine addition product of an ether is used as the brominating agent. 9 Chlorinated lower aliphatic hydrocarbons, ethers, ketones, di-lower alkyl-lower alkanoic acid amides, if desired in the presence of a buffer such as an organic or inorganic base or a tertiary organic aromatic base. 9. The method according to claim 8, wherein the bromination is carried out in 10. A process according to any of claims 1 to 9, in which pyridine hydrobromide perbromide is used in pyridine. 11. The method according to any one of claims 1 to 10, wherein the reaction is carried out at low temperature or room temperature. 12. The method according to claim 10 or 11, wherein the bromination is carried out at 0 to +20°C. 13. A process according to any of claims 1 to 12, wherein the 5,6-dipromo addition product is oxidized with chromium trioxide or with chromic acid in an aromatic tertiary nitrogen base. 14. The method according to claim 13, wherein the oxidation is carried out in the base used in the bromination. 15. A method according to claim 13 or 14, wherein the oxidation is carried out at a temperature of -10 to about +30°C. 16. The method according to claim 14 or 15, wherein pyridine is used as the base. 17 Claims 1 to 1 in which hydrogen bromide is removed by treating the chromic acid oxidation product with an inorganic basic agent
The method described in any of Section 5. 18. The method according to claim 17, wherein lithium halide is used in the presence of a basic salt of an alkali metal or alkaline earth metal. 19. The method according to claim 18, wherein lithium bromide is used in the presence of lithium carbonate. 20 Claim 18, which eliminates hydrogen bromide in dialkylamide of lower aliphatic carboxylic acid
The method according to item 19. 21. The method according to claim 20, which uses dimethylformamide. 22. The method according to any one of claims 19 to 21, wherein the reaction is carried out at 80 to 150°C. 23. The method according to any one of claims 1 to 15, wherein hydrogen bromide is eliminated using a nitrogen-containing aromatic base. 24 Formula () in which R 1 is an acylthio group and R 2 is a hydrogen atom from compounds in which R 1 and R 2 in formula () both represent a 6,7-C・C bond
By known methods for producing compounds of
24. The method according to any one of claims 1 to 23, wherein a 4,6-dien-3-one derivative having a 17α-propionalbitedo-acetal side chain is treated with a thiocarboxylic acid. 25. The process of claim 24, comprising treatment with about 1.5 to 3.5 moles of thiocarboxylic acid in a lower alkanol having 1 to 7 carbon atoms at 0 to 120°C. 26. The method according to claim 24, which is operated in absolute alcohol at 50-100°C. 27. The method according to any one of claims 24 to 26, wherein the reaction is carried out with a lower thiocarboxylic acid having 1 to 7 carbon atoms. 28 Claim 2 to be reacted with thioacetic acid
The method described in Section 7. 29. The method according to any one of claims 24 to 28, wherein the compound obtained by the method according to any one of claims 24 to 28 is treated with a compound of hexavalent chromium in a mineral acid solution. 30. The method of claim 29, wherein the oxidation is carried out using hexavalent chromium in a sulfuric acid solution, with or without the addition of acetone. 31. Any one of claims 24 to 28, wherein the oxidation of the compound obtained by any of the methods 24 to 28 above is carried out with chromium trioxide in a lower carboxylic acid having 1 to 7 carbon atoms. Method described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH7696/75 | 1975-06-13 | ||
| CH769675A CH612953A5 (en) | 1975-06-13 | 1975-06-13 | Process for the preparation of steroid carbolactones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6056998A JPS6056998A (en) | 1985-04-02 |
| JPS6357438B2 true JPS6357438B2 (en) | 1988-11-11 |
Family
ID=4329149
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6824976A Granted JPS52256A (en) | 1975-06-13 | 1976-06-12 | Production of steroidd carboxylic acid lactone |
| JP16662584A Granted JPS6056998A (en) | 1975-06-13 | 1984-08-10 | Manufacture of steroid-carboxylic acid lactone |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6824976A Granted JPS52256A (en) | 1975-06-13 | 1976-06-12 | Production of steroidd carboxylic acid lactone |
Country Status (12)
| Country | Link |
|---|---|
| JP (2) | JPS52256A (en) |
| AT (1) | AT356299B (en) |
| BE (1) | BE842870A (en) |
| CA (1) | CA1065849A (en) |
| CH (2) | CH612953A5 (en) |
| DE (1) | DE2625723A1 (en) |
| DK (1) | DK142992C (en) |
| FR (1) | FR2313934A1 (en) |
| GB (1) | GB1548259A (en) |
| MX (1) | MX3537E (en) |
| NL (1) | NL7606350A (en) |
| SE (1) | SE416951B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3330084A1 (en) * | 1983-08-17 | 1985-03-07 | Schering AG, 1000 Berlin und 4709 Bergkamen | 7 alpha -Alkoxycarbonyl-3-oxo-17 alpha -pregn-4-ene-21,17-carbolactones and their 21-carboxylic acid salts, process for the preparation thereof, and pharmaceutical products containing these |
| JPS6095799A (en) * | 1983-10-31 | 1985-05-29 | Nec Corp | Programmable read-only memory |
| US8334375B2 (en) | 2009-04-10 | 2012-12-18 | Evestra, Inc. | Methods for the preparation of drospirenone |
| CN108047299B (en) * | 2017-12-29 | 2021-11-09 | 广西万德药业有限公司 | Preparation method of important intermediate of canrenone |
| CN113528607B (en) * | 2021-08-08 | 2023-07-11 | 浙江神洲药业有限公司 | A kind of chemical-enzymatic method for preparing spironolactone |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1250818B (en) * | 1963-10-01 | 1967-09-28 | G. D. Searle & Co., Chicago, 111. (V. St. A.) | Process for the production of 3-oxozl4.asteroids |
| US3682894A (en) * | 1970-02-24 | 1972-08-08 | Searle & Co | Process for preparing 3-oxo-delta4,6-steroids |
| DE2248834A1 (en) * | 1972-10-05 | 1974-04-11 | Hoechst Ag | METHOD FOR MANUFACTURING BETA (3-KETO-7 ALPHA-ACETYLTHIO-17BETA-HYDROXY4-ANDROSTEN-17 ALPHA-YL) -PROPIONIC ACID GAMMA -LACTONE |
| DE2251476A1 (en) * | 1972-10-20 | 1974-05-02 | Hoechst Ag | PROCESS FOR THE PRODUCTION OF BETA (3-KETO-7 ALPHA-THIOACYL-17 BETA-HYDROXY4-ANDROSTEN-17 ALPHA -YL) -PROPIONIC ACID GAMMA -LACTONES |
-
1975
- 1975-06-13 CH CH769675A patent/CH612953A5/en not_active IP Right Cessation
-
1976
- 1976-05-21 SE SE7605799A patent/SE416951B/en not_active IP Right Cessation
- 1976-06-09 DE DE19762625723 patent/DE2625723A1/en not_active Ceased
- 1976-06-11 FR FR7617760A patent/FR2313934A1/en active Granted
- 1976-06-11 AT AT425476A patent/AT356299B/en not_active IP Right Cessation
- 1976-06-11 CA CA254,684A patent/CA1065849A/en not_active Expired
- 1976-06-11 GB GB2430576A patent/GB1548259A/en not_active Expired
- 1976-06-11 MX MX30176U patent/MX3537E/en unknown
- 1976-06-11 DK DK264476A patent/DK142992C/en active
- 1976-06-11 NL NL7606350A patent/NL7606350A/en unknown
- 1976-06-11 BE BE167857A patent/BE842870A/en not_active IP Right Cessation
- 1976-06-12 JP JP6824976A patent/JPS52256A/en active Granted
-
1979
- 1979-04-05 CH CH318579A patent/CH617443A5/en not_active IP Right Cessation
-
1984
- 1984-08-10 JP JP16662584A patent/JPS6056998A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| AT356299B (en) | 1980-04-25 |
| MX3537E (en) | 1981-02-10 |
| DE2625723A1 (en) | 1976-12-23 |
| CH612953A5 (en) | 1979-08-31 |
| NL7606350A (en) | 1976-12-15 |
| DK142992C (en) | 1981-10-05 |
| DK142992B (en) | 1981-03-09 |
| GB1548259A (en) | 1979-07-11 |
| CH617443A5 (en) | 1980-05-30 |
| SE416951B (en) | 1981-02-16 |
| JPS6159320B2 (en) | 1986-12-16 |
| CA1065849A (en) | 1979-11-06 |
| DK264476A (en) | 1976-12-14 |
| JPS52256A (en) | 1977-01-05 |
| BE842870A (en) | 1976-12-13 |
| FR2313934B1 (en) | 1978-10-20 |
| FR2313934A1 (en) | 1977-01-07 |
| ATA425476A (en) | 1979-09-15 |
| JPS6056998A (en) | 1985-04-02 |
| SE7605799L (en) | 1976-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5626616B2 (en) | Method for preparing drospirenone | |
| HU185184B (en) | Process for the preparation of 3beta,7beta,15-trihydroxy-5-and rosten-17-on and 3,15-dipivaletes thereof | |
| PT90227B (en) | PROCESS FOR THE PREPARATION OF 9-ALPHA-HYDROXY-17-METHYLENE STEROIDS | |
| JP2721002B2 (en) | Improvements in the synthesis of 6-methylene derivatives of androsta-1,4-diene-3,17-dione | |
| JPS596880B2 (en) | Method for producing D-homosteroid | |
| JPS6340198B2 (en) | ||
| KR20040097201A (en) | Process to prepare eplerenone | |
| JPS6357438B2 (en) | ||
| JP5430603B2 (en) | Guggulsterone and method for producing guggulsterol | |
| US3682983A (en) | Preparation of {66 {11 {11 -17 ethinyl steroids | |
| US4119625A (en) | Process for the manufacture of steroid carboxylic acids and the esters thereof | |
| CA1085820A (en) | Method for the preparation of esters | |
| US4192802A (en) | Process for the manufacture of steroid carboxylic acid lactones | |
| JPH05509287A (en) | 11β-substituted 16α,17α-methylene-estra-4,9-dien-3-one | |
| JP4629030B2 (en) | New process for preparing 17-halogenated 19-norsteroid compounds and intermediates | |
| JPH0725792B2 (en) | Process for producing 20-isocyano-20-sulfonyl-delta 16-steroid | |
| HU183086B (en) | Process for forming hydroxy-acetyl side chain of pregnane-type steroides | |
| US3761498A (en) | New process of preparation of steroids | |
| KR100836323B1 (en) | Method for preparing 4- (17α-substituted-3-oxoestra-4,9-diene-11β-yl) benzaldehyde- (1E or 1 ′)-oxime | |
| CS232737B2 (en) | Method of production of new delta (1,3,5)-3-chloropregnane derivatives | |
| Johns | 12. alpha., 13. beta.-Etiojervane analog of testosterone | |
| EP0071178B1 (en) | Acyloxysteroids and process for producing same | |
| US3157680A (en) | Preparation of 16-alkyl-16-dehydropregnenolone | |
| JP2004513178A (en) | 4- (17α-methyl-substituted 3-oxoestradi-4,9-dien-11β-yl) benzaldehyde- (1E or 1Z) -oxime | |
| IE44534B1 (en) | Ethers of 11 -hydroxy steroids and processes for the preparation thereof |